HOME >> BIOLOGY >> NEWS
Astrazeneca announces EU marketing approval for Faslodex(TM)

Alderley Park, UK, 12 March 2004: AstraZeneca announced today that it has received European marketing approval for its new breast cancer drug FASLODEXTM (fulvestrant). The novel drug is indicated for the treatment of postmenopausal women with receptor-positive locally advanced or metastatic breast cancer, for disease relapse or progression on or after therapy with an anti-oestrogen such as tamoxifen. 'Faslodex' has been launched in the USA since May 2002, and more recently in Brazil in July 2003.

Breast cancer affects 1 in 9 women at some point in their lives and although many tumours are detected early and treated successfully, a large number of women still go on to be diagnosed with advanced breast cancer. The goal of treatment for these women is to achieve an effective disease response and to enable the patient to maintain good quality of life for as long as is feasibly possible. Hormonal agents such as aromatase inhibitors and tamoxifen are standard therapy in postmenopausal women with advanced breast cancer, providing an effective and well-tolerated treatment option. However, in time tumour cells can grow resistant to treatment with these hormonal therapies and as a result there is a need for new agents to which tumours are not resistant. 'Faslodex' is an exciting new type of therapy, which brings new choices for women with advanced disease, extending the sequence of 'patient-friendly' hormonal therapies that can be used to control the disease.

'Faslodex' is a novel therapy, the first of a new type, with a unique mode of action. The new drug is an oestrogen receptor antagonist with no agonist effects that binds, blocks and degrades the oestrogen receptor in breast cancer cells. This mode of action is different to the aromatase inhibitors that work by reducing the amount of oestrogen in a woman's body. It is also different to tamoxifen, which blocks the oestrogen receptor but which also has some oestrogenic actions which can be associated w
'"/>

Contact: Alison Wright
alison.k.wright@astrazeneca.com
44-162-523-0076
Shire Health International
12-Mar-2004


Page: 1 2 3

Related biology news :

1. Secretary of Energy announces seven E.O. Lawrence Award Winners
2. Popular Science announces Third Annual Brilliant 10
3. The American Phytopathological Society announces 2004 awards
4. NSF announces six FIBR awards to tackle some of biologys most challenging questions
5. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
6. JGI announces community sequencing program portfolio
7. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
8. National Corn Growers Association announces valuable maize genome data now available to scientists
9. DFG announces three percent budget increase
10. Chemical Society announces EPA awards for environmentally friendly technology
11. Nanosphere announces genetic detection advance in Nature Biotechnology

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2019)... ... 2019 , ... According to the World Health Organization , over a ... chlamydia, gonorrhea, trichomoniasis (or "trich") and syphilis. And that’s not counting HIV. , ... accounted for the largest number of HIV diagnoses (9,807), followed by Hispanic/Latino men (7,436) ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... learning cloud solutions, today introduced Data Science Workstations-as-a-Service as part of its dedicated, ... from BOXX Technologies, Cirrascale Data Science Workstations feature NVIDIA® Quadro RTX™ GPUs for ...
(Date:6/14/2019)... , ... June 14, 2019 , ... Molecular diagnostics segment ... to be $8,760 million in 2019. Major segments that are expected to drive ... all broken out and forecasted as segments in Kalorama’s The World Molecular Diagnostics ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation and ... led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which ... The CAR enables the final product to produce chemicals in the hopes that the ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... demonstrate an efficient delivery system for the sustained release of human placental stem ... gel system was able to deliver CM into the injured kidney, where it ...
(Date:5/15/2019)... RIVER FALLS, Wis. (PRWEB) , ... May 16, ... ... uniform oil and water mixtures. As a result, food and beverage products rely ... However, today, consumers demand more natural sounding label declarations. This paradigm shift triggers ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The new Liquid Nitrogen Best ... being asked to store cellular products being used in adoptive therapy research ... world leaders, who have shared their expertise in building and managing facilities to ...
Breaking Biology Technology:
Cached News: